Trials / Recruiting
RecruitingNCT06649162
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,000 (estimated)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy
Conditions
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2027-03-01
- Completion
- 2027-03-01
- First posted
- 2024-10-18
- Last updated
- 2024-10-18
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06649162. Inclusion in this directory is not an endorsement.